The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSkinbiotherap. Regulatory News (SBTX)

Share Price Information for Skinbiotherap. (SBTX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.75
Bid: 8.50
Ask: 9.00
Change: -0.10 (-1.13%)
Spread: 0.50 (5.882%)
Open: 8.85
High: 8.85
Low: 8.75
Prev. Close: 8.85
SBTX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Jun 2017 10:38

RNS Number : 6698H
SkinBioTherapeutics PLC
09 June 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SkinBioTherapeutics

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

YES

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

NO

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

NO

An event changing the breakdown of voting rights

NO

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

SPREADEX LTD

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

30/05/2017

6. Date on which issuer notified:

08/06/2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary 1 -

3,233,333

3,233,333

2,933,333

2,933,333

2.47%

GB00BF33H870

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

CFD/SPREADBET

501,445

0.42%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,434,778

2.89%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

DAVID CORBEN

15. Contact telephone number:

01727 895135

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFLMLTMBJMMFR
Date   Source Headline
11th Apr 202411:44 amRNSHolding(s) in Company
5th Apr 20247:00 amRNSConversion Notice & Total Voting Rights
22nd Mar 20247:00 amRNSHalf-year Report
18th Mar 202411:36 amRNSHolding(s) in Company
18th Mar 20247:00 amRNSNew research project and CSO to return to academia
12th Mar 20247:00 amRNSConversion Notice and Total Voting Rights
8th Mar 20249:43 amRNSNotice of Results
28th Feb 202412:41 pmRNSConversion notice and alternative financing
27th Feb 20247:00 amRNSPositive Interim AxisBiotix Acne study results
20th Feb 20247:00 amRNSDermatonics to launch Once Heel Balm in AMEA
9th Feb 20247:00 amRNSConversion Notice and Total Voting Rights
6th Feb 20247:31 amRNSDermatonics Full Year trading update
26th Jan 20247:00 amRNSCompletion of Acquisition of Dermatonics
25th Jan 20247:00 amRNSAcquisition of Dermatonics
25th Jan 20247:00 amRNS£5.0m Convertible Bond Facility & First Drawdown
29th Dec 202310:49 amRNSResult of AGM
29th Dec 20238:13 amRNSUpdate on transaction timelines to early 2024
6th Dec 20237:00 amRNSNotice of AGM and posting of Annual Report
30th Nov 20235:25 pmRNSFinal Results
30th Nov 20237:00 amRNSAxisBiotix-Psâ„¢ to launch on Amazon UK
24th Nov 20237:00 amRNSHolding(s) in Company
23rd Nov 20233:37 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
21st Nov 20237:00 amRNSResult of Retail Offer
17th Nov 20237:00 amRNSResult of Placing
16th Nov 20234:35 pmRNSRetail Offer
16th Nov 20234:33 pmRNSPlacing and Retail Offer
25th Oct 20237:25 amRNSAcne study, Trading and Auditor updates
19th Oct 20237:00 amRNSExtension of Croda contract for SkinBiotixâ„¢
15th Sep 20239:00 amRNShealth authority approval for AxisBiotix in France
5th Sep 20237:00 amRNSUpdate on acne programme
31st Jul 202312:51 pmRNSHolding(s) in Company
21st Jun 20237:00 amRNSRegulatory Approval
14th Jun 20234:46 pmRNSBusiness progress update
10th May 20237:00 amRNSSkinBiotix and AxisBiotix Update
14th Apr 20237:00 amRNSDirector/PDMR Shareholding
28th Mar 20231:45 pmRNSReplacement Half-year Report
28th Mar 20237:00 amRNSHalf-year Report
27th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20235:18 pmRNSDirector/PDMR Shareholding
9th Mar 20235:18 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSAxisBiotix-Ps™ approved for launch in Europe
20th Feb 202311:17 amRNSHolding(s) in Company
31st Jan 202311:15 amRNSResult of General Meeting
30th Jan 20234:28 pmRNSHolding(s) in Company
30th Jan 20239:00 amRNSHolding(s) in Company
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
6th Jan 20237:44 amRNSNotice of General Meeting - Replacement
6th Jan 20237:00 amRNSNotice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.